Topics

FDA Accepts and Grants Priority Review for Bristol-Myers’ BLA for Lisocabtagene Maraleucel for Large B-Cell Lymphoma

09:53 EST 14 Feb 2020 | Speciality Pharma Journal

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel), the company’s autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment …

Original Article: FDA Accepts and Grants Priority Review for Bristol-Myers’ BLA for Lisocabtagene Maraleucel for Large B-Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts and Grants Priority Review for Bristol-Myers’ BLA for Lisocabtagene Maraleucel for Large B-Cell Lymphoma"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...